Actinium Faces Derivative Suit Over FDA Application Claims
By Emilie Ruscoe · May 14, 2025, 11:24 PM EDT
Officers and directors of biopharmaceutical company Actinium Pharmaceuticals Inc. face a shareholder derivative action accusing them of breaching their fiduciary duties after the company's lead product candidate failed to secure a...
To view the full article, register now.